A biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
This biotech has a reliable royalty revenue stream from its proprietary pegylation technology which makes drugs less toxic, and more effective. It has a solid balance sheet and some interesting compounds in the pipeline. It has just sold off a portfolio of drugs to fix the balance sheet. Undervalued due to years of questionable decisions by management, the new CEO has now put the house in order, which promises appreciation to fair value and more gains if one of the drugs in the pipeline pans out.